8Alves C, Batel-Marques F, Macedo AF. A meta-analysis of seri- ous adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer [J]. Diabetes Res ClinPraet, 2012, 98 ( 2 ) : 271-284.
9Toth PP. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus [J]. Postgrad Med, 2011, 123 ( 4 ) : 46.
10Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The me- tabolism and disposition of the oral dipeptidyl pep-tidase-4 inhibitor, Linagliptin, in humans [J]. DrugMetab Dispos, 2010, 38 ( 4 ) : 667.
4Hanefeld M. The metabolic syndrome: roots, myths, and facts. In: Hanefeld M,Leonhardt W, eds. The metabolic syndrome. Jena, Gustav Fischer, 1997,13-24.
5Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes, 2000, 49:975-980.
6Age, body mass index and glucose tolerance in 11 European population-based surveys. Diabet Med, 2002, 19: 558-565.
7Drivsholm T, Ibsen H, Schroll M, et al. Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med, 2001, 18:126-132.
8decode study Group, on behalf of the European Diabetes Epidemiology. Glucose tolerance and cardiovascular mortality : comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med, 2001, 161:397-405.
9Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 2001, 24(suppl 1): S5-S20.
10WHO. Report of a WHO conslultation. Definition, diagnosis and classification of diabetes mellitus and its complications(Part 1). Geneva.1999.
3Kurihara T,Westenskow PD,Friedlander M.Hypoxiain-ducible factor (HIF)/vascular endothelial growth factor(VEGF)signaling in the retina[J].Adv Exp Med Biol,2014,801:275-281.
